Product Code: PH208
THE BOTTOM LINE:
In response to the Physician Payment Sunshine Act and other reporting- and rate-based legislation, life science companies have formalized their Fair Market Value (FMV) processes. Appropriate financial relationships with healthcare providers are the result of standardized rate cards, clear KOL scoring systems and regular access to reliable FMV rates.
Use Global Key Opinion Leader Compensation 2015 to stay compliant and keep pace with the rapid, worldwide formalization of FMV processes and legislation. Explore FMV rates developed from cutting-edge primary research and proprietary analytics. Understand physician tiering processes and the evolution of rate cards, and investigate the consequences of the Sunshine Act and its ex-US equivalents.
KEY QUESTIONS
ANSWERING CRITICAL QUESTIONS FOR OUR CLIENTS
This report's benchmarks and analyses address FMV values across tiers, company types, regions and activity categories for specialists, primary care physicians and non-MD providers; KOL selection factors and changes in companies' KOL scoring processes and comprehensive rate card and fee schedules. Life science executives can use Global Key Opinion Leader Compensation 2015 to stay compliant and keep pace with the rapid, worldwide formalization of FMV processes and legislation.
KEY QUESTIONS ANSWERED IN THIS REPORT
- What are the most relevant factors to consider when determining FMV compensation?
- Are my company's FMV payments for specialists and non-MDs defensible and clear? How do our rates compare to other companies' compensation?
- How do subspecialists fit into companies' FMV determination processes?
- What criteria should companies weigh when scoring and tiering KOLs?
- What does an effective rate card look like? How much detail should it have?
- What factors should companies take into account when formalizing their payments?
- What are the benefits of standardized FMV protocols, and how can companies avoid regulatory scrutiny?
- How is the US Sunshine Act influencing transparency requirements in other markets?
KEY FINDINGS
CRITICAL FINDINGS ON GLOBAL KEY OPINION LEADER COMPENSATION
The following principles are signposts to help companies improve and enhance their fair market value processes. While these points are not inclusive of all elements in the report, they emphasize its central and most critical concepts.
- 1. PREPARE NOW FOR UPCOMING REGULATORY MANDATES.
- 2. CREATE FORMAL RATE CARDS AND SCORING SYSTEMS TO STANDARDIZE INTERNAL FMV PROCESSES.
Base Hourly Rates for PCPs and Non-MD Providers, by Geography
- 3. USE RATES TO BENCHMARK YOUR FMV PAYMENTS AND GUARANTEE REGULATORY COMPLIANCE.
- 4. USE KOL CRITERIA RATINGS TO SCORE AND TIER THOUGHT LEADERS - A PIVOTAL STEP IN FORMALIZING THE THOUGHT LEADER SELECTION PROCESS.
Table of Contents
Executive Summary
- Key Recommendations to Ensure FMV Compliance
The Future of FMV: A Review of the US Sunshine Act and Other Physician Payment Regulations
- The History of the Physician Payment Sunshine Act
- That Was Then, This Is Now: A Comparative Look Between Preand Post-Sunshine Act Environments
- Physician and Industry Reactions to the US Sunshine Act
- The Future of the Sunshine Act and Other Regulatory Efforts
Fair Market Value Rates and Their Determination
- Aggregated Fair Market Value Rates: Specialist Key Opinion Leaders
- Aggregated Fair Market Value Rates: Primary Care Physicians and NonMD Providers
- The Interplay of the Factors in Determining FMV
KOL Selection Criteria Drive Companies' Tiering and FMV Strategies
- Score KOL's Background to Standardize Selection Process
- Rate Card Analyses: Understanding the Key Factors Behind Standardized FMV Rates
Executive Summary
Key Recommendations to Ensure FMV Compliance
The Future of FMV: A Review of the US Sunshine Act and Other Physician Payment Regulations
- The History of the Physician Payment Sunshine Act
- Figure 1.1: Selected Pre-Sunshine Act District and State Physician Payment Restrictions
- Figure 1.2: Individual States' Pre-Sunshine Act Reporting Requirements
- That Was Then, This Is Now: A Comparative Look Between Preand Post-Sunshine Act Environments
- Figure 1.3: US Physician Payment Sunshine Act Timeline
- Figure 1.4: Targeted Healthcare Audiences Not Covered within Sunshine Act, by State or District-Level Governance
- Figure 1.5: Individual States' Reporting Requirements Outside Sunshine Act's Scope
- Figure 1.6: Loi Bertrand or French Sunshine Act
- Physician and Industry Reactions to the US Sunshine Act
- The Future of the Sunshine Act and Other Regulatory Efforts
Fair Market Value Rates and Their Determination
- Aggregated Fair Market Value Rates: Specialist Key Opinion Leaders
- Figure 2.1: Base Hourly Rates for Specialists, by Tier Designation
- Figure 2.2: Base Hourly Rates for Specialists, by Company Type
- Figure 2.3: Base Hourly Rates for Specialists, by Geography
- Figure 2.4: Base Hourly Rates for Specialists for Selected Specialty Areas
- Table 2.1: Base Hourly Rates for Selected Surgical Subspecialties
- Figure 2.5: Hourly Rates for Specialists, by KOL Activity Category
- Aggregated Fair Market Value Rates: Primary Care Physicians and NonMD Providers
- Figure 2.6: Base Hourly Rates for PCPs and NonMD Providers, by Title
- Figure 2.7: Base Hourly Rates for PCPs and NonMD Providers, by Company Type
- Figure 2.8: Base Hourly Rates for PCPs and NonMD Providers, by Geography
- Figure 2.9: Hourly Rates for PCPs and NonMD Providers, by KOL Activity Category
- Table 2.2: FMV Rates for OB/GYN in Australia, Top 50 Pharma
- The Interplay of the Factors in Determining FMV
KOL Selection Criteria Drive Companies' Tiering and FMV Strategies
- Score KOL's Background to Standardize Selection Process
- Figure 3.1: Types of KOLs Used, by Company
- Figure 3.2: Average Ratings of KOL Selection Importance, by Therapeutic Area
- Figure 3.3: Average Ratings of KOL Selection Importance, by Geography
- Figure 3.4: Average Ratings of KOL Selection Importance, by Company Type
- Table 3.1: Average Selection Criteria Ratings for Top 10 Companies, by Therapeutic Area
- Table 3.2: Average Selection Criteria Ratings for Top 10 Companies, by Team Region
- Table 3.3: Average Selection Criteria Ratings for Top 50 Companies, by Therapeutic Area
- Table 3.4: Average Selection Criteria Ratings for Top 50 Companies, by Team Region
- Table 3.5: Average Selection Criteria Ratings for Small Pharma Companies, by Therapeutic Area
- Table 3.6: Average Selection Criteria Ratings for Small Pharma Companies, by Team Region
- Table 3.7: Average Selection Criteria Ratings for Device Companies, by Therapeutic Area
- Table 3.8: Average Selection Criteria Ratings for Device Companies, by Team Region
- Table 3.9: Average Selection Criteria Ratings for Other Company Types, By Therapeutic Area
- Table 3.10: Average Selection Criteria Ratings for Other Company Types, by Team Region
- Figure 3.5: Average Percentage of KOLs within Each Tier, by Company Type
- Figure 3.6: Average Percentage of KOLs within Each Tier, by Therapeutic Area
- Figure 3.7: Average Percentage of KOLs within Each Tier, by Geography
- Figure 3.8: Average Percentage of KOLs within Each Tier, by Company Type: Australia
- Figure 3.9: Average Percentage of KOLs within Each Tier, by Company Type: Canada
- Figure 3.10: Average Percentage of KOLs within Each Tier, by Company Type: Emerging Regions
- Figure 3.11: Average Percentage of KOLs within Each Tier, by Company Type: Japan
- Figure 3.12: Average Percentage of KOLs within Each Tier, by Company Type: Northern Europe
- Figure 3.13: Average Percentage of KOLs within Each Tier, by Company Type: United States
- Figure 3.14: Average Percentage of KOLs within Each Tier, by Company Type: Western Europe
- Rate Card Analyses: Understanding the Key Factors Behind Standardized FMV Rates
- Figure 3.15: Sample Rates for Advisory Board Chairs and Participants, by Company
- Figure 3.16: Sample Rates for Speaker Program Chairs and Speakers, by Company
